Brainomix 360 e-ASPECTS

The Brainomix 360 e-ASPECTS is a Class II radiological computer-assisted diagnostic software that utilizes artificial intelligence to process non-contrast CT brain images, generating an Alberta Stroke Program Early CT (ASPECTS) score to assist medical imaging professionals in characterizing ischemic brain tissue injury. Its purpose is to enhance diagnostic accuracy for clinicians evaluating the extent of disease within 24 hours of a patient's last known well time, as demonstrated by improved reader performance in clinical studies.

Brainomix 360 e-ASPECTS is a Class II radiological computer-assisted diagnostic software, now cleared for market distribution, that assists clinicians in the evaluation of brain tissue abnormalities. Designed for medical imaging professionals, its core purpose is to characterize ischemic brain tissue injury and assess the extent of disease within 24 hours of a patient's last known well time, by processing non-contrast CT brain images. The device's market entry is underpinned by its determination of substantial equivalence to existing legally marketed devices and adherence to standard regulatory controls, including good manufacturing practices and proper labeling. The scientific foundation of Brainomix 360 e-ASPECTS lies in its utilization of artificial intelligence to automatically generate an Alberta Stroke Program Early CT (ASPECTS) score from these CT scans. This AI-driven methodology encompasses automated image registration, segmentation, and detailed analysis of ASPECTS regions, augmented by visualizations of contributing voxels and volume calculations, thereby enhancing diagnostic precision. Clinical performance studies have substantiated the software's ability to improve reader accuracy, and recent modifications, such as an extended time window for use and adjusted patient selection criteria, have been validated to ensure no new safety or effectiveness concerns arise compared to predicate devices.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the AI algorithm within Brainomix 360 e-ASPECTS specifically improve upon human interpretation of ASPECTS scores, particularly in subtle or ambiguous cases?; What was the design of the clinical performance studies that demonstrated improved reader accuracy, and what were the specific metrics used to quantify this improvement?; Are there any specific limitations or edge cases where the Brainomix 360 e-ASPECTS software might provide inaccurate or misleading ASPECTS scores, and how are these mitigated?; How does the extended 24-hour time window for use impact the diagnostic utility and clinical decision-making compared to shorter timeframes, and what evidence supports its safety and effectiveness in this broader window?; Beyond ASPECTS scoring, does the software provide any additional prognostic or therapeutic guidance based on the identified ischemic changes, or is it purely a diagnostic aid?